Utility of thieno[2,3-b] pyridine derivatives in the synthesis of some condensed heterocyclic compounds with expected biological activity

A. Y. Hassan¹, M. T. Sarg^{2*}, M. M. Said³ and S. A. El-Sebaey²

*Correspondence: m.t.sarg@hotmail.com

¹Department of Chemistry, Faculty of Science (Girls), Al-Azhar University, Nasr City, Cairo, Egypt.

²Department of Organic Chemistry, Faculty of Pharmacy (Girls), Al-Azhar University, Nasr City, Cairo, Egypt.

³Department of Organic Chemistry, Faculty of Pharmacy, Cairo University, Egypt.

Abstract

On the pharmaceutical account of the reported anticancer activity of thieno[2,3-b] pyridine and condensed thieno[2,3-b] pyridine, new compounds containing thieno[2,3-b] pyridine condensed with each of pyridine, cyclopentyl, tetrahydroquinoline, pyrimidine, 1,6-naphthiridin, benzofuro[2,3-b] pyridine, imidazo[1,2-c] pyrimidine, [1,2,3] triazolo[1,5-a] pyrimidine were synthesized through different chemical reactions. The obtained compounds were evaluated for their *in vitro* antitumor activity against Liver HepG-2 and Breast MCF-7 cell lines compared to the reference drug (doxorubicin). Compounds **5**, **7**, **12**, **23**, **24**, **37** and **39** were found to be the most active against both cell lines exhibiting IC₅₀ values ranging from 10.33-43.90 µM/L and 9.70-48.80 µM/L against HepG-2 and MCF-7 cell lines; respectively. From which compound **5** was the most active compound exerting comparable activity to the reference drug against both cell lines, showing IC₅₀ values 10.33 and 9.70 µM/L comparable to doxorubicin that exerted IC₅₀ values 8.55 and 8.90 µM/L against HepG-2 and MCF-7 cell lines; respectively.

Keywords: Thienopyridine, pyridothienopyridine, pyridothienopyrimidine, anticancer, liver HepG-2, breast MCF-7

Introduction

The thieno[2,3-b]pyridine derivatives occupy special place and have attracted considerable attention because of their broad pharmacological activities, including anticancer [1-9], antiviral [10-13], anti-inflammatory [14-17], antimicrobial [18,19], antidiabetic [20-23], antihypertensive [24-26] and osteogenic [27,28] activities, in addition to treatment of CNS disorders [29-31].

The aforementioned biological activities stimulated our interest for the synthesis of several new condensed heterocyclic compounds containing thieno[2,3-b] pyridine moiety condensed with each of pyridine, cyclopentyl, tetrahydroquinoline, pyrimidine, 1,6-naphthiridin, benzofuro[2,3-b] pyridine, imidazo[1,2-c] pyrimidine, [1,2,3] triazolo[1,5-a] pyrimidine. The new condensed heterocyclic derivatives possessing latent functional substituents appear promising to fulfill the objectives of our biological activity studies and the desired chemical transformations.

Results and discussion

Chemistry

The o-aminonitrile thienopyridine derivative **2** was synthesized through treatment of the pyridine thione derivative **1** with chloroacetonitrile in presence of sodium hydroxide [32]. "(Scheme 1)". Fusion of the o-aminonitrile derivative **2** with cyclic ketones namely; cyclopentanone and cyclohexanone

in the presence of anhydrous zinc chloride [33] yielded the tetracyclic compounds **3** and **4**; respectively. Reactions utilizing cyclohexanone resulted in higher yields of the product compared to cyclopentanone, a fact that could be attributed to the steric flexibility of cyclohexanone [34]. Reactions of compound **2** with ethyl methyl ketone furnished the tricyclic pyridothienopyridine derivative **5**. The reactions of α-aminonitriles with various cyclic ketones in presence of Lewis acid were reported to be achieved through the nucleophilic attack of the lone pair of amino nitrogen on the carbonyl carbon to form Schiff's base, followed by complex formation between Lewis acid, zinc chloride and the nitrile triple bond that accelerates the intramolecular cyclization [35].

Furthermore, the o-aminonitrile derivative **2** was refluxed with malononitrile in presence of a catalytic amount of triethylamine [36] to yield pyridothienopyridine-3-carbonitrile derivative **6**.

Reagents: i) ClCH_2CN / NaOH / absolute EtOH ; ii) $\text{C}_6\text{H}_5\text{COCH}_2\text{COCH}_3$ / ZnCl_2 ; iii) $\text{CH}_3\text{COCH}_2\text{CH}_3$ / ZnCl_2 ; iv) CNCH_2CN / absolute EtOH / Et_3N .

Scheme 1. Synthetic pathway for compounds **3**, **4**, **5** and **6**. The interaction of o-aminonitrile derivative **2** with cyanoacetone in dry DMF [37] gave the corresponding pyridothienopyridine-3-carbonitrile derivative **7** (Scheme 2). Cyclization of compound **7** upon refluxing in formic acid only [38] afforded the pyrimidinone derivative **8**. The IR spectrum of compound **8** showed a broad absorption band at 3416 cm^{-1} due to the tautomeric OH group besides a band at 1719 cm^{-1} corresponding to $\text{C}=\text{O}$ function.

Moreover, treatment of o-aminonitrile **2** with benzoyl acetone in presence of sodium ethoxide [39] yielded compound **9** that was further refluxed with malononitrile in presence of a catalytic amount of piperidine [39] to yield pyridothienonaphthyridine-3-carbonitrile derivative **10**.

Furthermore, refluxing of equimolar amounts of compounds **2** and cyanothioacetamide in ethanol containing a catalytic amount of piperidine [40] afforded pyridothienopyridine-3-carbonitrile derivative **11** which its ^1H NMR spectrum showed two deuterium oxide exchangeable singlets at δ 4.50 and 6.90 ppm attributed to NH_2 and NH protons; respectively. When o-aminonitrile derivative **2** was treated with benzofuran-2(3H)-one in dioxane containing a catalytic amount of triethylamine, it furnished a single product identified as compound **12**.

Reagents: i) $\text{CH}_3\text{COCH}_2\text{CN}$ / DMF; ii) HCOOH ; iii) $\text{C}_6\text{H}_5\text{COCH}_2\text{COCH}_3$ / NaOEt ; iv) CNCH_2CN / absolute EtOH / piperidine; v) $\text{CNCH}_2\text{CSNH}_2$ / absolute EtOH / piperidine; vi) $\text{C}_6\text{H}_5\text{C}_2\text{O}$ / dioxane / Et_3N .

Scheme 2. Synthetic pathways for compounds **7**, **8**, **9**, **10**, **11** and **12**.

The o-aminonitrile derivative **2** was subjected to partial hydrolysis by stirring with concentrated sulphuric acid [33] to yield 2-carboxamide derivative **13** (Scheme 3). The ^1H NMR spectrum of compound **13** displayed two deuterium oxide exchangeable singlets at δ 5.68 and δ 6.92 ppm corresponding to NH_2 and CONH_2 protons; respectively.

Acid-catalyzed bis-nucleophilic cyclocondensation of o-aminocarboxamide derivative **13** with acid chlorides namely; benzoyl chloride and chloroacetyl chloride in glacial acetic

acid [33] furnished pyrimidinone derivatives **14a** and **14b**; respectively. The ^1H NMR spectra of compounds **14a** and **14b** revealed two deuterium oxide exchangeable singlets at δ 12.60, 10.50 ppm corresponding to pyrimidine NH protons; respectively. However, ^1H NMR spectrum of compound **14b** showed an additional singlet at δ 3.07 ppm integrated for two protons corresponding to $\text{CH}_2\text{-Cl}$ protons.

The o-aminonitrile derivative **2** was reacted with triethyl orthoformate [41] which underwent a nucleophilic substitution reaction in the presence of acetic anhydride introducing a replaceable ethoxy group furnishing the intermediate compound **15**. The ^1H NMR spectrum of compound **15** displayed a triplet at δ 1.06 ppm and a quartet at δ 3.44 ppm attributed to ethyl protons of the ethoxymethylene group. In addition to a singlet due methine proton at δ 7.25 ppm.

Furthermore, compound **15** upon reaction with excess hydrazine hydrate [42] yielded novel pyridothienopyrimidine derivative **16**. The reaction mechanism was reported [41] to be accomplished through addition of a hydrazine molecule on the enamine double bond followed by elimination of an ethanol molecule and intramolecular cyclization to yield the target compound **16**. The ^1H NMR spectrum of compound **16** showed two deuterium oxide exchangeable singlets at δ 6.06 and δ 8.90 ppm corresponding to the vicinal amino and imino groups; respectively.

Similarly, compound **2** was refluxed with formic acid to yield pyridothienopyrimidinone derivative **17** which its synthesis was rationalized via a sequence of N-formylation followed by cyclization processes involving the interaction between nucleophilic hydroxyl group and electrophilic nitrile carbon to give the 4-iminoxazine intermediate which underwent rearrangement to yield the pyrimidinone ring [33]. The ^1H NMR spectrum of the compound **17** displayed a deuterium oxide exchangeable singlet corresponding to OH proton at δ 12.80 ppm.

Reagents: i) $\text{conc. H}_2\text{SO}_4$ / Stirring at r.t.; ii) RCOCl / CH_3COOH ; iii) $\text{HC(OC}_2\text{H}_5)_3$ / AC_2O ; iv) NH_2NH_2 ; v) HCOOH .

Scheme 3. Synthetic pathways for compounds **13**, **14a,b**, **15**, **16** and **17**.

The interaction of the o-aminonitrile derivative **2** with phenyl isothiocyanate in presence of pyridine [36] led to the formation of pyridothienopyrimidine-2-thione **18**. (Scheme 4)". The ¹H NMR spectrum of compound **18** showed two deuterium oxide exchangeable singlets at δ 7.10 and 9.75 ppm attributed to pyrimidine NH and imino protons; respectively.

A facile reaction occurred when o-aminonitrile derivative **2** was refluxed in excess formamide [43] to furnish the corresponding 4-aminopyrimidine derivative **19**. The reaction mechanism was reported to be proceeding first through o-cyanoformamidine formation followed by intramolecular cyclization via nucleophilic attack of the lone pair of the formamide amino group on the electrophilic nitrile carbon [43].

Diazotization of compound **2** was accomplished through its reaction with cold hydrochloric acid and saturated aqueous sodium nitrite solution to yield thienopyridine-3-diazonium chloride **20** which was further coupled with compounds bearing active methylene functions namely; malononitrile and ethyl cyanoacetate [44] to afford the corresponding hydrazono derivatives **21** and **22**; respectively. The ¹H NMR spectra of compounds **21** and **22** revealed deuterium oxide exchangeable singlets at δ 8.50 and δ 8.28 ppm attributed to NH protons; respectively.

Hydrazono derivatives **21** and **22** were cyclized upon treatment with hydrazine hydrate in boiling ethanol [44] to afford the expected 3,5-diaminopyrazole derivative **23** and 3-amino-5-oxopyrazole derivative **24**. The ¹H NMR spectrum of compound **23** revealed a deuterium oxide exchangeable singlet at δ 9.85 ppm integrated for four protons attributed to two NH₂ protons. The ¹H NMR spectrum of the compound **24** displayed three deuterium oxide exchangeable singlets corresponding to pyrazole-NH, pyrazole-C₃-NH₂ and thiophene-C₃-NH protons at δ 7.00, 7.22 and 8.60 ppm; respectively.

Reagents: i) C₆H₅-NCS/ dioxane/ pyridine; ii) HCONH₂; iii) NaNO₂/ HCl/ 0-5°C; iv) CNCH₂CN/ absolute EtOH; v)

CNCH₂COOC₂H₅/ absolute EtOH; vi) NH₂NH₂/ absolute EtOH.
Scheme 4. Synthetic pathways for compounds **18**, **19**, **20**, **21**, **22**, **23** and **24**.

Compound **2** was also reacted with ethylene diamine in the presence of carbon carbon disulphide disulfide [45] to afford 2-imidazolylthienopyridine derivative **25** (Scheme 5)". The reaction mechanism is proposed to proceed through addition of carbon disulphide and an ethylene diamine molecules on the nitrile function followed by the elimination of 2-thioxoimidazolidine moiety to yield thiocarboxamide derivative which further reacted with one molecule of ethylene diamine with simultaneous elimination of ammonia and hydrogen sulphide molecules to yield the imidazolidine ring. ¹H NMR spectrum of compound **25** showed two deuterium oxide exchangeable singlets at δ 6.90 and 7.20 ppm attributed to NH and NH₂ protons; respectively.

Compound **25** was further subjected to cyclization into tetracyclic imidazopyridothienopyrimidine systems in different ways [45]. Treatment of compound **25** with triethyl orthoformate gave the unsubstituted imidazopyridothienopyrimidine **26**, while refluxing of compound **25** with benzaldehyde yielded the corresponding 5-phenylimidazopyridothienopyrimidine **27**. On the other hand, imidazopyridothienopyrimidine-5-thione **28** was obtained by heating compound **25** with in boiling pyridine.

The ¹H NMR spectrum of compound **27** displayed a singlet at δ 8.71 ppm corresponding to pyrimidine-C₂ proton besides to a deuterium oxide exchangeable singlet at δ 9.65 ppm attributed to NH proton. Furthermore, the ¹H NMR spectrum of compound **28** revealed a deuterium oxide exchangeable singlet at δ 9.85 ppm attributed to NH proton.

Reagents: i) NH₂(CH₂)₂NH₂/ CS₂; ii) HC(OC₂H₅)₃/gl.AcOH; iii) C₆H₅-CHO/absolute EtOH; iv) CS₂/pyridine.

Scheme 5. Synthetic pathways for compounds **25**, **26**, **27** and **28**. The thienopyridine o-aminoester derivative **29** was prepared through the reaction of pyridine thione **1** with ethyl chloroacetate in presence of sodium hydroxide [46] (Scheme 6)". The amino group in o-aminoester derivative **29** was diazotized by nitrososulfuric acid followed by

the addition of sodium azide solution [47] to yield azide derivative **30**. Compound **30** was further reacted with different nitriles namely; malononitrile and 2-(benzo[d]thiazol-2-yl) acetonitrile by refluxing in sodium methoxide [47] to yield pyridothienotriazolopyrimidinones **31a** and **31b**; respectively. Moreover, methylthiocarbonothioylamino derivative **32** was prepared in a one pot reaction by treating a vigorously stirred solution of o-amino ester derivative **29** with carbon disulphide and sodium hydroxide solution [48] to yield the sodium salt of dithiocarbamic acid which was not isolated and was further treated with dimethyl sulphate. Compound **32** was further cyclized by refluxing with hydrazine hydrate in ethanol [48] to yield 2-thioxopyridothienopyrimidin-4-one **33**. The ¹H NMR spectrum of compound **32** revealed a singlet at δ 2.71 ppm attributed to S-CH₃ protons. In addition to a deuterium oxide exchangeable singlet at δ 7.32 ppm attributed to NH proton. However, the ¹H NMR spectrum of compound **33** revealed two deuterium oxide exchangeable signlets at δ 4.30 and δ 6.61 ppm attributed to NH₂ and pyrimidine NH protons; respectively.

Furthermore, treatment of o-aminoester derivative **29** with triethyl orthoformate in presence of sodium azide [49] afforded the 3-tetrazolylthienopyridine-2-carboxylate derivative **34** which was further subjected to hydrazinolysis to give 2,3-diaminopyridothienopyrimidinone **35**. The ¹H NMR spectrum of compound **35** revealed two deuterium oxide exchangeable singlets at δ 4.10 and 6.80 ppm attributed to pyrimidine-C₂-NH₂ and pyrimidine-N₃-NH₂ protons; respectively.

Reagents: i) $\text{ClCH}_2\text{COOC}_2\text{H}_5/\text{NaOH}/\text{EtOH}$; ii) $\text{NaNO}_2/\text{H}_2\text{SO}_4/\text{NaN}_3$; iii) $\text{CNCH}_2\text{R}/\text{NaOMe}$; iv) $\text{CS}_2/\text{NaOH}/\text{DMSO}$; v) $(\text{CH}_3)_2\text{SO}_4$; vi) $\text{NH}_2\text{NH}_2/\text{absolute EtOH}$; vii) $\text{CH}(\text{OC}_2\text{H}_5)_3/\text{NaN}_3/\text{gl.AcOH}$; viii) NH_2NH_2 .

Scheme 6. Synthetic pathways for compounds **29**, **30**, **31a,b**,

32,33, 34 and **35**.

The 3-carbohydrazide derivative **36** was prepared by treatment of o-aminoester **29** with hydrazine hydrate [46]. “(Scheme 7)”. Compound **36** was further refluxed with triethyl orthoformate in presence acetic anhydride and with acetic anhydride only [50] to yield the formimidate derivative **37** and the acetamide derivative **38**; respectively. The ¹H NMR spectrum of compound **37** displayed two singlets at δ 7.87 ppm and δ 8.36 ppm due to N=CH proton and pyrimidine C₂ proton; respectively.

Furthermore, the reaction of acid hydrazide derivatives with ethyl acetoacetate were reported to yield either pyrazolone derivatives [50,51] or the open chain imine derivative [50]. However, compound **36** upon reaction with ethyl acetoacetate in presence of sodium ethoxide [50] yielded the pyrazolone derivative **39** which its ¹H NMR spectrum revealed a singlet at δ 2.26 ppm integrated for five protons corresponding to pyrazole-C₃-CH₃ and pyrazole-CH₂ protons. It also showed a deuterium oxide exchangeable singlet at δ 16.53 ppm attributed to H-bonded NH₂ protons.

Reagents: i) $\text{NH}_2\text{NH}_2/\text{absolute EtOH}$; ii) $\text{HC}(\text{C}_2\text{H}_5)_3/\text{AC}_2\text{O}$; iii) AC_2O ; iv) $\text{CH}_3\text{COCH}_2\text{COOC}_2\text{H}_5/\text{NaOEt}$.

Scheme 7. Synthetic pathways for compounds **36**, **37**, **38** and **39**.

Biological evaluation

The synthesized compounds were screened for their *in vitro* cytotoxic activity against human hepatocellular liver carcinoma (HepG2). (Table 1) and human breast cancer cell line (MCF-7) (Table 2). Doxorubicin was used as the reference drug.

The pyrido[3',2':4,5]thieno[3,2-b]pyridine derivative **5** exhibited highly potent anticancer activity against both HepG2 (Figure 1) and MCF-7 cell lines (Figure 2) showing IC₅₀ values 10.33 and 9.70 μM/L; respectively which represents comparable activity to the reference drug doxorubicin (IC₅₀ 8.555 and 8.90 μM/L). However, replacement of only one methyl group and retaining the 2- methyl function as in compound **7** resulted in decrease in the anticancer activity

against both cell lines. Also, fusion of benzofuopyridine ring to the thieno[2,3-b]pyridine nucleus as in compound **12** resulted in potent anticancer activity against HepG2 cell line and moderate activity against MCF-7 cell line.

It is to be noted that, introduction of a pyrazole ring to the thienopyridine backbone either through an azo junction as in 3,5-diaminopyrazole derivative **23** or a hydrazo function

in 3-aminopyrazol-5-one derivative **24** or a carbonyl group as in 3-methyl pyrazol-5-one derivative **39** afforded significant activity against both cell lines. Also, the introduction of ethoxymethyleneamino moiety at the N₃ of pyrimidine-4-one ring fused to the thieno[2,3-b]pyridine back bone as in compound **37** also resulted in marked increase in activity against both HepG2 and MCF-7 cell lines.

Table 1. Six dose growth inhibition percent and IC₅₀ values of the tested compounds against HepG2 cell line.

Sample concentration (µg/mL) Compound No.	Growth inhibition %						IC ₅₀ (µM/L)
	50	25	12.5	6.25	3.13	1.6	
3	77.17	62.86	35.25	18.74	7.68	1.82	<u>57.93</u>
4	79.09	67.37	48.13	21.84	15.95	6.38	<u>39.66</u>
5	93.09	89.17	84.36	70.02	48.68	42.3	<u>10.33</u>
6	63.74	40.14	24.86	10.74	3.82	0.00	<u>>100</u>
7	86.58	72.59	57.42	39.76	26.53	13.95	<u>29.95</u>
8	69.47	53.28	37.31	24.62	10.81	2.18	<u>62.50</u>
9	40.68	29.17	25.31	17.46	8.24	2.78	<u>>100</u>
10	31.07	20.82	13.58	4.7	1.44	0.00	<u>>100</u>
11	89.17	80.24	67.55	56.48	31.86	9.63	<u>30.99</u>
12	91.06	80.13	61.35	46.88	29.52	12.94	<u>19.92</u>
13	28.14	16.72	8.83	2.78	0.00	0.00	<u>>100</u>
14b	61.82	52.83	30.26	12.84	7.04	1.27	<u>69.62</u>
15	86.28	68.58	27.62	15.35	8.94	2.76	<u>60.04</u>
16	78.64	53.18	32.61	21.06	10.28	2.47	<u>75.15</u>
17	21.47	7.82	3.26	1.08	0.00	0.00	<u>>100</u>
18	57.25	39.18	21.09	10.96	3.87	1.41	<u>99.87</u>
21	46.53	30.82	16.58	5.74	1.96	0.00	<u>>100</u>
22	79.84	52.77	34.59	23.21	14.54	7.49	<u>59.31</u>
23	88.62	80.54	56.17	37.84	19.07	8.58	<u>27.77</u>
24	89.59	86.21	74.38	35.5	18.38	6.86	<u>22.90</u>
25	84.37	46.83	30.54	18.35	10.28	3.46	<u>87.87</u>
26	87.88	47.72	30.13	17.27	10.04	5.87	<u>82.91</u>
27	67.48	38.14	26.11	15.19	6.03	2.82	<u>88.52</u>
28	84.15	75.07	50.41	29.18	12.37	5.26	<u>35.38</u>
30	56.72	38.04	19.27	7.66	2.42	0.00	<u>>100</u>
31a	54.38	39.25	18.57	6.74	1.87	0.00	<u>>100</u>
31b	58.97	27.08	16.86	8.25	3.17	0.00	<u>92.16</u>
32	26.16	10.82	5.18	1.87	0.00	0.00	<u>>100</u>
34	80.28	61.81	26.76	14.64	7.43	1.92	<u>56.92</u>
35	68.67	51.86	30.4	16.68	7.92	2.77	<u>73.90</u>
36	86.21	71.49	36.76	21.83	10.62	5.44	<u>57.98</u>
37	79.32	67.24	52.03	31.88	20.77	13.42	<u>33.47</u>
38	77.83	63.28	46.42	27.82	12.78	5.07	<u>41.71</u>
39	87.92	78.52	39.07	20.86	10.47	1.53	<u>43.90</u>
Doxorubicin	89.05	85.71	83.10	78.68	69.68	51.75	<u>8.55</u>

Table 2. Six dose growth inhibition percent and IC₅₀ values of the tested compounds against MCF-7 cell line.

Sample concentration (µg/mL) Compound No.	Growth inhibition %						IC ₅₀ (µM/L)
	50	25	12.5	6.25	3.13	1.6	
3	85.54	73.18	54.26	27.02	10.87	3.74	<u>34.69</u>
4	67.38	38.26	26.03	14.62	7.83	1.94	<u>>100</u>
5	91.22	85.08	74.66	61.22	50.18	36.44	<u>9.70</u>
6	60.04	42.38	16.04	28.62	5.26	1.04	<u>>100</u>
7	87.22	78.64	61.46	26.68	12.44	3.25	<u>31.47</u>
8	54.61	32.18	20.62	12.46	3.82	0.00	<u>>100</u>
9	25.74	10.57	3.72	0.00	0.00	0.00	<u>>100</u>
10	41.38	20.55	7.68	1.87	0.00	0.00	<u>>100</u>
11	86.24	61.42	37.81	21.73	9.52	2.84	<u>54.24</u>
12	87.25	73.79	38.94	16.66	7.27	1.44	<u>43.25</u>
13	35.49	10.28	3.85	0.00	0.00	0.00	<u>>100</u>
14b	57.16	21.27	7.82	3.85	0.00	0.00	<u>>100</u>
15	56.36	21.08	10.82	4.57	1.28	0.00	<u>>100</u>
16	84.64	68.31	45.47	27.74	14.81	7.57	<u>48.80</u>
17	26.06	13.82	5.28	1.94	0.00	0.00	<u>>100</u>
18	85.72	52.64	27.08	16.26	7.82	2.04	<u>59.17</u>
21	52.47	36.16	28.91	13.66	4.15	1.78	<u>>100</u>
22	71.62	46.91	17.13	8.71	2.59	0.88	<u>72.15</u>
23	91.66	85.22	80.54	52.98	39.41	25.87	<u>14.95</u>
24	89.11	81.38	60.26	34.42	23.57	14.81	<u>26.63</u>
25	63.73	32.15	17.82	8.22	3.11	0.00	<u>>100</u>
26	70.34	36.81	17.26	8.18	3.22	0.00	<u>>100</u>
27	56.40	19.09	7.24	1.96	0.00	0.00	<u>>100</u>
28	82.62	63.16	34.94	20.65	12.02	4.83	<u>54.78</u>
30	51.71	26.82	9.24	2.78	0.00	0.00	<u>>100</u>
31a	41.28	23.44	14.07	7.22	1.94	0.00	<u>>100</u>
31b	53.46	26.84	9.58	1.89	0.00	0.00	<u>>100</u>
32	61.37	38.65	20.28	10.96	4.15	1.26	<u>93.15</u>
34	67.14	29.62	12.85	6.28	1.53	0.00	<u>>100</u>
35	40.84	31.62	23.49	16.46	9.59	2.18	<u>>100</u>
36	74.62	48.24	27.66	10.88	3.62	0.00	<u>89.48</u>
37	78.93	64.36	48.62	32.04	16.93	7.84	<u>37.31</u>
38	53.28	26.17	7.86	3.22	0.00	0.00	<u>>100</u>
39	83.68	72.53	41.74	26.28	13.46	7.82	<u>43.63</u>
Doxorubicin	90.76	88.45	84.26	77.78	70.82	55.16	<u>8.90</u>

Figure 1. Percent growth inhibition curves of most active compounds and reference drug (doxorubicin) against HepG2 cell line.

Figure 2. Percent growth inhibition curves of most active compounds and reference drug (doxorubicin) against MCF-7 cell line.

Experimental Chemistry

All melting points were measured on Electro thermal LA 9000 SERIS, Digital Melting point Apparatus and are uncorrected. IR spectra (KBr) were recorded on FT-IR 200 spectrophotometer (u cm^{-1}), pharmaceutical analytical unit, Faculty of Pharmacy, Al-Azhar University. $^1\text{H-NMR}$ spectra were recorded in (DMSO-d_6) at 300 MHz on a Varian Gemini NMR spectrometer (δ , ppm) using TMS as an internal standard, Resarch Service Unit, Faculty of Science, Cairo University. Mass spectra were recorded on GC Ms-QP 5050A mass spectrometer at 70 eV and microanalytical data were performed in Regional center for Mycology and Biotechnology, Al-Azhar University. Thin layer chromatography was performed on precoated (0.25mm) silica gel GF₂₅₄ plates (E. Merck, Germany). Compounds were detected with 254 nm UV lamp.

General procedure for the synthesis of compounds 3, 4 and 5

An equimolar mixture of compound **2** (2.65 g, 10 mmol) and cyclic/alicyclic ketones (10 mmol), in presence of anhydrous ZnCl_2 (0.68g, 5 mmol) was fused at 120–130° C for 5h. The reaction mixture was allowed to cool, triturated with H_2O

and neutralized with sodium hydroxide 10%. The separated solid was filtered off, washed with water, left to dry then recrystallized from ethanol.

9-Amino-4-methyl-2-phenyl-7,8-dihydro-6H-cyclopenta[b]pyrido[3',2':4,5]-thieno[2,3-e]pyridine; 3

Brown powder; yield 1.70 g (51%); m.p.: >360°C. **Anal. Calcd.** (%) for $\text{C}_{20}\text{H}_{17}\text{N}_3\text{S}$ (331.43): C, 72.48; H, 5.17; N, 12.68. **Found** (%): C, 72.53; H, 5.28; N, 12.74. **IR (KBr, cm^{-1}):** 3443, 3226 (NH_2); 3090 (CH-aromatic); 2930 (CH-aliph.); 1644 (C=N); 1563 (C=C). **$^1\text{H NMR}$ (DMSO-d_6 , δ ppm):** 2.60-2.80 (m, 6H, cyclopentyl-C-H); 3.02 (s, 3H, CH_3); 5.40 (s, 2H, NH_2 , D_2O exchangeable); 7.30-7.65 (m, 3H, C_6H_5 -C_{3,4,5}-H); 7.95 (s, 1H, C₃-H); 8.10-8.15 (m, 2H, C_6H_5 -C_{2,6}-H). **Mass spectrum, m/z (%):** 329 (M^+ -2, 0.03), 55(100.00).

10-Amino-4-methyl-2-phenyl-6,7,8,9-tetra-hydropyrido[3',2':4,5]thieno[3,2-b]-quinoline; 4

Buff crystals; yield 2.76 g (80%); m.p.: 220–222°C. **Anal. Calcd.** (%) for $\text{C}_{21}\text{H}_{19}\text{N}_3\text{S}$ (345.46): C, 73.01; H, 5.54; N, 12.16. **Found** (%): C, 73.04; H, 5.52; N, 12.22. **IR (KBr, cm^{-1}):** 3430, 3300 (NH_2); 3075 (CH-aromatic); 2922, 2855 (CH-aliph.); 1647 (C=N); 1570 (C=C). **MS, m/z (%):** 345 (M^+ , 3.47), 80 (100.00).

4-Amino-2,3,9-trimethyl-7-phenylpyrido[3',2':4,5]thieno[3,2-b]pyridine; 5

Brown powder; yield 1.75 g (55%); m.p.: >360°C. **Anal. Calcd.** (%) for $\text{C}_{19}\text{H}_{17}\text{N}_3\text{S}$ (319.42): C, 71.44; H, 5.36. **Found** (%): C, 71.46; H, 5.39. **IR (KBr, cm^{-1}):** 3300, 3175 (NH_2); 3042 (CH-aromatic); 2961, 2922 (CH-aliph.); 1647 (C=N); 1558 (C=C); 1345, 1021 (C-S-C). **$^1\text{H NMR}$ (DMSO-d_6 , δ ppm):** 1.91 (s, 3H, C₃-CH₃); 2.56 (s, 3H, C₂-CH₃); 2.73 (s, 3H, C₉-CH₃); 5.40 (s, 2H, NH_2 , D_2O exchangeable); 7.30-7.65 (m, 3H, C_6H_5 -C_{3,4,5}-H); 8.10-8.28 (m, 3H, C₈-H & C_6H_5 -C_{2,6}-H). **MS, m/z (%):** 319 (M^+ , 2.13), 57 (100.00).

Synthesis of 2,4-diamino-9-methyl-7-phenyl-pyrido[3',2':4,5]thieno[3,2-b]pyridine-3-carbonitrile; 6

Compound **2** (2.65 g, 10 mmol) and an equimolar amount of malononitrile (0.66 g, 10 mmol) were refluxed in absolute ethanol (30 mL) containing 5 drops of triethylamine for 9 h. The reaction mixture was allowed to cool and the obtained solid was filtered off, washed with ethanol and recrystallized from DMF/ethanol.

Brown powder; yield 2.76 g (83%); m.p.: > 360°C. **Anal. Calcd.** (%) for $\text{C}_{18}\text{H}_{13}\text{N}_5\text{S}$ (331.39): C, 65.24; H, 3.95; N, 21.13. **Found** (%): C, 65.27; H, 3.96; N, 21.21. **IR (KBr, cm^{-1}):** 3407, 3332, 3240, 3174 (NH_2); 3000 (CH-aromatic); 2917, 2845 (CH-aliph.); 2213 ($\text{C}\equiv\text{N}$); 1650 (C=N); 1569 (C=C). **MS, m/z (%):** 331 (M^+ , 0.19), 67 (100.00).

Synthesis of 4-amino-2,9-dimethyl-7-phenyl-pyrido[3',2':4,5]thieno[3,2-b]pyridine-3-carbonitrile; 7

A mixture of chloroacetone (0.46 g, 0.4 mL, 5 mmol) and potassium cyanide (0.33 g, 5 mmol) was refluxed in dry DMF (10 mL) for 10 min. to which a solution of compound

2 (1.33 g, 5 mmol) in dry DMF (20 mL) was added dropwise while stirring and reflux was continued for another 15 h. The reaction mixture was allowed to cool, then poured onto crushed ice and the product was filtered off, washed with water and recrystallized from ethanol.

Brown powder; yield 0.88 g (53%); m.p.: 101-102°C. **Anal. Calcd.** (%) for $C_{19}H_{14}N_4S$ (330.41): C, 69.07; H, 4.27; N, 16.96. **Found** (%): C, 69.12; H, 4.31; N, 17.08. **IR (KBr, cm^{-1}):** 3426, 3300 (NH_2); 3000 (CH-aromatic); 2924 (CH-aliph.); 2205 ($C\equiv N$); 1640 ($C=N$); 1590 ($C=C$). **1H NMR (DMSO- d_6 , δ ppm):** 2.61 (s, 3H, C_2-CH_3); 2.89 (s, 3H, C_9-CH_3); 6.60 (s, 2H, NH_2 , D_2O exchangeable); 7.51-7.60 (m, 3H, $C_6H_5-C_{3,4,5}-H$); 7.87 (s, 1H, C_8-H); 8.10-8.28 (m, 2H, $C_6H_5-C_{2,6}-H$). **MS, m/z (%)**: 332 ($M^+ + 2$, 2.02), 331 ($M^+ + 1$, 1.52), 330 (M^+ , 0.51), 328 ($M^+ - 2$, 1.77), 78 (100.00).

Synthesis of 5,7-dimethyl-9-phenylpyrido[3',2'':4',5']thieno[2',3':5,6]-pyrido[4,3-d]pyrimidin-4(3H)-one; 8
Compound **7** (1.65 g, 5 mmol) was refluxed in excess formic acid (20 mL) for 10h. The reaction mixture was allowed to cool then poured onto crushed ice to yield a solid product which was filtered, washed with water then allowed to dry. The product was recrystallized from DMF/ethanol.

Black crystals; yield 1.55 g (87%); m.p.: > 360°C. **Anal. Calcd.** (%) for $C_{20}H_{14}N_4OS$ (358.42): C, 67.02; H, 3.94; N, 15.63. **Found** (%): C, 67.04; H, 3.99; N, 15.77. **IR (KBr, cm^{-1}):** 3416 (OH tautomer); 3275 (NH); 2920, 2851 (CH-aliph.); 1719 ($C=O$); 1642 ($C=N$); 1576 ($C=C$). **MS, m/z (%)**: 359 ($M^+ + 1$, 7.62), 357 ($M^+ - 1$, 4.85), 80 (100.00).

Synthesis of 3-acetyl-4-amino-9-methyl-2,7-diphenylpyrido[3',2':4,5]-thieno[3,2-b]pyridine; 9

Equimolar amounts of compound **2** (1.33 g, 5 mmol) and benzoylacetone (0.81 g, 5 mmol) in ethanolic sodium ethoxide solution [(prepared by dissolving sodium metal (0.12 g, 5 mmol) in absolute ethanol (30 mL)], were refluxed for 10 h. The reaction mixture was allowed to cool, and then poured onto ice-cold water. The obtained precipitate was filtered off and recrystallized from ethanol.

Brown powder; yield 0.93 g (45%); m.p.: 79-81°C. **Anal. Calcd.** (%) for $C_{25}H_{19}N_3OS$ (409.50): C, 73.32; H, 4.68; N, 10.26. **Found** (%): C, 73.39; H, 4.66; N, 10.34. **IR (KBr, cm^{-1}):** 3321, 3174 (NH_2); 3059 (CH-aromatic); 2970, 2923 (CH-aliph.); 1690 ($C=O$); 1580 ($C=N$); 1551 ($C=C$). **1H NMR (DMSO- d_6 , δ ppm):** 2.84 (s, 3H, $COCH_3$); 3.02 (s, 3H, C_9-CH_3); 7.20 (s, 2H, NH_2 , D_2O exchangeable); 7.48-7.62 (m, 6H, two $C_6H_5-C_{3,4,5}-H$); 7.98 (s, 1H, C_8-H); 8.16-8.22 (m, 4H, two $C_6H_5-C_{2,6}-H$). **MS, m/z (%)**: 409 (M^+ , 4.39), 77 (100.00).

Synthesis of 2-amino-4,7-dimethyl-5,9-diphenylpyrido[3',2':4,5]thieno[3,2-h]-[1,6]naphthyridine-3-carbonitrile; 10

Compound **9** (2.05 g, 5 mmol) and an equimolar amount of malononitrile (0.33 g, 5 mmol) were refluxed in absolute ethanol (30 mL) containing a catalytic amount of piperidine

(3 drops) for 15 h. The reaction mixture was allowed to cool and the obtained solid was filtered, washed with ethanol and left to dry. It was recrystallized from DMF/ethanol.

Brown powder; yield 1.97g (86%); m.p.: > 360°C. **Anal. Calcd.** (%) for $C_{28}H_{19}N_5S$ (457.55): C, 73.50; H, 4.19; N, 15.31. **Found** (%): C, 73.48; H, 4.24; N, 15.52. **IR (KBr, cm^{-1}):** 3332, 3240 (NH_2); 3000 (CH-aromatic); 2919 (CH-aliph.); 2212 ($C\equiv N$); 1650 ($C=N$); 1567 ($C=C$). **MS, m/z (%)**: 456 ($M^+ - 1$, 0.38), 78 (100.00).

Synthesis of 4-amino-9-methyl-7-phenyl-2-thioxo-1,2-dihydropyrido [3',2':4,5]thieno[3,2-b]pyridine-3-carbonitrile; 11

A mixture of compound **2** (2.65 g, 10 mmol) and cyanothioacetamide (1 g, 10 mmol) was refluxed for 8 h in absolute ethanol (30 mL) containing 3 drops of piperidine. The reaction mixture was allowed to cool, then poured onto ice-cold water, and neutralized with hydrochloric acid (10%). The separated solid was filtered and recrystallized from ethanol.

Black powder; Yield 1.91 g (55%); m.p.: > 360°C. **Anal. Calcd.** (%) for $C_{18}H_{12}N_4S_2$ (348.44): C, 62.05; H, 3.47; N, 16.08. **Found** (%): C, 62.11; H, 3.49; N, 16.22. **IR (KBr, cm^{-1}):** 3427, 3275 (NH , NH_2); 3100 (CH-aromatic); 2926 (CH-aliph.); 2213 ($C\equiv N$); 1621 ($C=N$); 1562 ($C=C$); 1526, 1358, 1120, 1079 (I, II, III, IV bands $N-C=S$). **1H NMR (DMSO- d_6 , δ ppm):** 2.84 (s, 3H, CH_3); 4.50 (s, 2H, NH_2 , D_2O exchangeable.); 6.90 (s, 1H, NH , D_2O exchangeable.); 7.40-7.60 (m, 3H, $C_6H_5-C_{3,4,5}-H$); 7.78 (s, 1H, C_8-H); 8.15 (d, 1H, $J = 8.4$ Hz, $C_6H_5-C_2-H$); 8.24 (d, 1H, $J = 8.1$ Hz, $C_6H_5-C_6-H$). **MS, m/z (%)**: 348 (M^+ , 0.82), 53 (100.00).

Synthesis of 11-amino-4-methyl-2-phenyl[1]benzofuro[2,3-b]pyrido-[3',2':4,5]thieno[2,3-e]pyridine; 12

An equimolar mixture of compound **2** (2.65 g, 10 mmol) and benzofuran-2(3H)-one (1.34 g, 10 mmol) was refluxed for 14 h in dioxane (30 mL) containing a catalytic amount of triethyl amine (3 drops). The reaction mixture was allowed to cool then poured onto crushed ice to yield a solid product which was filtered and recrystallized from ethanol.

Dark yellow crystals; yield 2.54g (67%); m.p.: 50-52°C. **Anal. Calcd.** (%) for $C_{23}H_{15}N_3OS$ (381.45): C, 72.42; H, 3.96; N, 11.02. **Found** (%): C, 72.47; H, 3.98; N, 11.13. **IR (KBr, cm^{-1}):** 3326, 3192 (NH_2); 3057 (CH-aromatic); 2925 (CH-aliph.); 1662 ($C=N$); 1590 ($C=C$); 1286, 1051 ($C-O-C$). **1H NMR (DMSO- d_6 , δ ppm):** 2.84 (s, 3H, CH_3); 6.90 (s, 2H, NH_2 , D_2O exchangeable); 7.49- 7.68 (m, 5H, $C_6H_5-C_{3,4,5}-H$ & $C_6H_5-C_{3',4'}-H$); 7.69 (s, 1H, C_3-H); 7.79 (d, 2H, $J = 7.2$ Hz, $C_6H_5-C_{2,5}-H$); 7.82 (d, 2H, $J = 9.9$ Hz, $C_6H_5-C_{2,6}-H$). **MS, m/z (%)**: 380 ($M^+ - 1$, 0.59), 106 (100.00).

Synthesis of 3-amino-4-methyl-6-phenylthieno[2,3-b]pyridin-2-carboxamide; 13

Compound **2** (2.65 g, 10 mmol) was stirred in 25 ml conc. H_2SO_4 for 19 h at room temperature. The reaction mixture was poured drop wise over crushed ice. The solid product was filtered, washed with water, left to dry and recrystallized

from ethanol.

Brown powder; Yield 2.39 g (85%); m.p.: > 360°C. **Anal. Calcd.** (%) for $C_{15}H_{13}N_3OS$ (283.35): C, 63.58; H, 4.62; N, 14.83. **Found** (%): C, 63.60; H, 4.65; N, 14.90. **IR (KBr, cm^{-1}):** 3327, 3185 (NH_2); 3075 (CH-aromatic); 2921 (CH-aliph.); 1649 (C=O); 1603 (C=N); 1563 (C=C). **1H NMR (DMSO- d_6 , δ ppm):** 3.01 (s, 3H, CH_3); 5.68 (s, 2H, C_3-NH_2 , D_2O exchangeable); 6.92 (s, 2H, $CONH_2$, D_2O exchangeable); 7.47-7.55 (m, 3H, $C_6H_5-C_{3,4,5}-H$); 7.77 (s, 1H, C_5-H); 7.90-8.24 (m, 2H, $C_6H_5-C_{2,6}-H$). **MS, m/z (%):** 283 (M^+ , 9.44), 44 (100.00).

General procedure for the synthesis of compounds 14a,b

A mixture of compound **13** (2.65 g, 10 mmol) and the appropriate acid chloride (10 mmol) namely; benzoyl chloride and chloroacetyl chloride was refluxed in acetic acid (10 mL) for 10 h. The reaction mixture was allowed to cool, and then poured onto ice-cold water. The separated solid was filtered, washed with water and recrystallized from ethanol.

9-Methyl-2,7-diphenylpyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4(3H)-one; 14a

Black powder; yield 1.75 g (48%); m.p.: 115-117°C. **Anal. Calcd.** (%) for $C_{22}H_{15}N_3OS$ (369.44): C, 71.52; H, 4.09; N, 11.37. **Found** (%): C, 71.51; H, 4.13; N, 11.42. **IR (KBr, cm^{-1}):** 3425 (OH tautomer); 3250 (NH); 3080 (CH-aromatic); 2924 (CH-aliph.); 1700 (C=O); 1564 (C=N). **1H NMR (DMSO- d_6 , δ ppm):** 3.02 (s, 3H, CH_3); 7.48-7.62 (m, 6H, two $C_6H_5-C_{3,4,5}-H$); 7.95 (d, 2H, $J=8$ Hz, $C_2-C_6H_5-C_{2,6}-H$); 8.00 (s, 1H, C_8-H); 8.10-8.30 (m, 2H, $C_7-C_6H_5-C_{2,6}-H$); 12.60 (s, 1H, OH, D_2O exchangeable). **MS, m/z (%):** 369 (M^+ , 2.37), 53 (100.00).

2-(Chloromethyl)-9-methyl-7-phenylpyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4(3H)-one; 14b

Black crystals; yield 2.43 g (72%); m.p.: > 360°C. **Anal. Calcd.** (%) for $C_{17}H_{12}ClN_3OS$ (341.81): C, 59.73; H, 3.54; N, 12.29. **Found** (%): C, 59.82; H, 3.57; N, 12.35. **IR (KBr, cm^{-1}):** 3421 (OH tautomer); 3280 (NH); 2914 (CH-aliph.); 1740 (C=O); 1636 (C=N); 1545 (C=C); 850 (C-Cl). **1H NMR (DMSO- d_6 , δ ppm):** 2.73 (s, 3H, CH_3); 3.07 (s, 2H, CH_2Cl); 7.40-7.70 (m, 4H, $C_6H_5-C_{3,4,5}-H$ & C_8-H); 8.10-8.25 (m, 2H, $C_6H_5-C_{2,6}-H$); 10.50 (s, 1H, OH, D_2O exchangeable). **MS, m/z (%):** 341 (M^+ , 1.02), 53 (100.00).

Synthesis of ethyl N-(2-cyano-4-methyl-6-phenylthieno[2,3-b]pyridin-3-yl)formimidate; 15

Compound **2** (2.65 g, 10 mmol) was refluxed with an equimolar amount of triethyl orthoformate (1.48 g, 1.64 mL, 10 mmol) in acetic anhydride (15 mL) for 8 h. The reaction mixture was allowed to cool, and then poured onto crushed ice. The obtained solid was filtered, washed with water and recrystallized from ethanol.

Black crystals; yield 2.28 g (71%); m.p.: > 360°C. **Anal. Calcd.** (%) for $C_{18}H_{15}N_3OS$ (321.40): C, 67.27; H, 4.70; N, 13.07. **Found** (%): C, 67.29; H, 4.68; N, 13.14. **IR (KBr, cm^{-1}):** 2919, 2850 (CH-aliph.); 2230 ($C\equiv N$); 1580 (C=N); 1462 (C=C); 1303, 1029

(C-O-C). **1H NMR (DMSO- d_6 , δ ppm):** 1.06 (t, 3H, $J=6.6$ Hz, CH_2CH_3); 3.01 (s, 3H, C_4-CH_3); 3.44 (q, 2H, $J=6.6$ Hz, CH_2CH_3); 7.25 (s, 1H, $C_3-N=CH$); 7.30-8.25 (m, 6H, C_6H_5 & C_5-H). **MS, m/z (%):** 321 (M^+ , 0.25), 319 (M^+-2 , 0.25), 67 (100.00).

Synthesis of 3-amino-4-imino-9-methyl-7-phenyl-3,4-dihydropyrido-[3',2':4,5]thieno[3,2-d]pyrimidine; 16

A mixture of compound **15** (3.21 g, 10 mmol) and excess hydrazine hydrate 99% (10 mL) was refluxed for 8 h. The reaction mixture was allowed to cool, and then triturated with ethanol. The separated solid was filtered and recrystallized from ethanol.

Brown powder; yield 2.05 g (67%); m.p.: 320-322°C. **Anal. Calcd.** (%) for $C_{16}H_{13}N_5S$ (307.37): C, 62.52; H, 4.26; N, 22.78. **Found** (%): C, 62.55; H, 4.30; N, 22.91. **IR (KBr, cm^{-1}):** 3302, 3196 (NH, NH_2); 3090 (CH-aromatic); 2921 (CH-aliph.); 1656 (C=N); 1560 (C=C). **1H NMR (DMSO- d_6 , δ ppm):** 3.02 (s, 3H, CH_3); 6.06 (s, 2H, NH_2 , D_2O exchangeable); 7.40-7.60 (m, 3H, $C_6H_5-C_{3,4,5}-H$); 8.02 (s, 1H, C_8-H); 8.21-8.24 (m, 2H, $C_6H_5-C_{2,6}-H$); 8.40 (s, 1H, C_2-H); 8.90 (s, 1H, $C_4=NH$, D_2O exchangeable). **MS, m/z (%):** 308 (M^++1 , 66.74), 307 (M^+ , 0.30), 306 (M^+-1 , 0.11), 53 (100.00).

Synthesis of 9-methyl-7-phenylpyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4(3H)-one; 17

Compound **2** (2.65 g, 10 mmol) was refluxed in excess formic acid (10 mL) for 16 h. The reaction mixture was allowed to cool, and then triturated by ethanol. The separated solid was filtered and recrystallized from ethanol.

Orange powder; yield 2.44 g (83%); m.p.: 270°C. **Anal. Calcd.** (%) for $C_{16}H_{11}N_3OS$ (293.34): C, 65.51; H, 3.78; N, 14.32. **Found** (%): C, 65.53; H, 3.82; N, 14.39. **IR (KBr, cm^{-1}):** 3416 (OH tautomer); 3200 (NH); 3061 (CH-aromatic); 2921 (CH-aliph.); 1650 (C=O); 1614 (C=N). **1H NMR (DMSO- d_6 , δ ppm):** 2.97 (s, 3H, CH_3); 7.40-7.60 (m, 3H, $C_6H_5-C_{3,4,5}-H$); 8.09 (s, 1H, C_8-H); 8.20-8.30 (m, 2H, $C_6H_5-C_{2,6}-H$); 8.38 (s, 1H, C_2-H); 12.80 (s, 1H, OH, D_2O exchangeable). **MS, m/z (%):** 293 (M^+ , 6.98), 61 (100.00).

Synthesis of 4-imino-9-methyl-3,7-diphenyl-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2(1H)-thione; 18

An equimolar mixture of compound **2** (2.65 g, 10 mmol) and phenyl isothiocyanate (1.35 g, 10 mmol) was refluxed in dry dioxane (20 mL) containing 1 mL of dry pyridine for 10 h. The reaction was allowed to cool to room temperature, then poured onto crushed ice, neutralized with hydrochloric acid (10%) and the obtained product was filtered off, washed with water and left to dry. The product was recrystallized from ethanol.

Buff crystals; yield 2.49 g (62%); m.p.: 125-127°C. **Anal. Calcd.** (%) for $C_{22}H_{16}N_4S_2$ (400.52): C, 65.97; H, 4.03; N, 13.99. **Found** (%): C, 66.01; H, 4.07; N, 14.12. **IR (KBr, cm^{-1}):** 3427, 3207 (NH); 3026 (CH-aromatic); 2921 (CH-aliph.); 1644 (C=N); 1592 (C=C); 1547, 1236, 1150, 1066 (I, II, III, IV bands N-C=S). **1H NMR (DMSO- d_6 , δ ppm):** 3.00 (s, 3H, CH_3); 7.10 (s, 1H, NH, D_2O exchangeable); 7.12-7.15 (m, 6H, two $C_6H_5-C_{3,4,5}-H$);

7.30-7.40 (m, 3H, N₃-C₆H₅-C_{2,6}-H & C₈-H); 7.48 (d, 2H, J=7.8Hz, C₇-C₆H₅-C_{2,6}-H); 9.75 (s, 1H, C₄=NH, D₂O exchangeable). **MS, m/z (%)**: 401 (M⁺+1, 5.56), 80 (100.00).

Synthesis of 4-amino-9-methyl-7-phenylpyrido[3',2':4,5]thieno[3,2-d] pyrimidine; 19

An equimolar mixture of compound **2** (2.65 g, 10 mmol) and formamide (0.45 g, 1.1 mL, 10 mmol) was fused for 10 h at 170–180°C. The reaction mixture was allowed to cool, then triturated by methanol and stirred at room temperature for 30 min. The precipitated solid was filtered, washed with cold methanol, and recrystallized from ethanol.

Black crystals; yield 1.48 g (51%). m.p.: >360°C. **Anal. Calcd.** (%) for C₁₆H₁₂N₄S (292.36): C, 65.73; H, 4.14; N, 19.16. **Found** (%): C, 65.77; H, 4.13; N, 19.27. **IR (KBr, cm⁻¹)**: 3426, 3340 (NH₂); 2926 (CH-aliph.); 1630 (C=N); 1554 (C=C). **¹H NMR (DMSO-d₆, δ ppm)**: 3.02 (s, 3H, CH₃); 7.42-7.60 (m, 5H, C₆H₅-C_{3,4,5}-H & NH₂); 8.06 (s, 1H, C₈-H); 8.22-8.24 (m, 2H, C₆H₅-C_{2,6}-H); 8.39 (s, 1H, C₂-H). **MS, m/z (%)**: 292 (M⁺, 10.67), 72 (100.00).

Synthesis of 2-cyano-4-methyl-6-phenylthieno[2,3-b]pyridine-3-diazonium chloride; 20

A suspension of compound **2** (2.65 g, 10 mmol) in concentrated hydrochloric acid (3 mL) was cooled to 0-5°C in an ice bath to which an ice cold solution of sodium nitrite (1.5 g, 20 mmol in 10 mL water) was added dropwise while cooling over a period of 15 minutes. The reaction mixture was then stirred for 30 minutes to yield crystals of the diazonium product **20**, which was filtered and used as such in next step.

General procedure for the synthesis of compounds 21 & 22
To an ice-cold mixture of active methylene compounds namely; malononitrile and ethyl cyanoacetate (10 mmol) and anhydrous sodium acetate (4 g, 50 mmol) in absolute ethanol (50 mL), an ice cold solution of compound **20** (3.12 g, 10 mmol) in absolute ethanol (10 mL), was added dropwise over a period 15 minutes while stirring and cooling in an ice bath. Stirring was then continued for 24 h at room temperature. The reaction mixture was then filtered and the obtained product was washed with ethanol.

[(2-Cyano-4-methyl-6-phenylthieno[2,3-b]pyridin-3-yl)hydrazono]-malononitrile; 21

Brown crystals; yield 2.93 g (86%); m.p.: > 360°C. **Anal. Calcd.** (%) for C₁₈H₁₀N₆S (342.38): C, 63.14; H, 2.94; N, 24.55. **Found** (%): C, 63.18; H, 2.95; N, 24.63. **IR (KBr, cm⁻¹)**: 3270 (NH); 3000 (CH-aromatic); 2926 (CH-aliph.); 2203 (C≡N); 1642 (C=N); 1566 (C=C). **¹H NMR (DMSO-d₆, δ ppm)**: 3.03 (s, 3H, CH₃); 7.50-7.54 (m, 3H, C₆H₅-C_{3,4,5}-H); 7.99 (s, 1H, C₅-H); 8.20-8.23 (m, 2H, C₆H₅-C_{2,6}-H); 8.50 (s, 1H, NH, D₂O exchangeable). **MS, m/z (%)**: 343 (M⁺+1, 14.71), 342 (M⁺, 2.94), 60 (100.00).

Ethyl 2-[(2-cyano-4-methyl-6-phenylthieno[2,3-b]pyridin-3-yl)hydrazono]-2-cyanoacetate; 22

Brown crystals; yield 2.68 g (69%); m.p.: 50-52°C. **Anal. Calcd.**

(%) for C₂₀H₁₅N₅O₂S (389.43): C, 61.68; H, 3.88; N, 17.98. **Found** (%): C, 61.69; H, 3.86; N, 18.12. **IR (KBr, cm⁻¹)**: 3250 (NH); 3002 (CH-aromatic); 2850 (CH-aliph.); 2205 (C≡N); 1698 (C=O); 1639 (C=N); 1574 (C=C); 1250, 1019 (C-O-C). **¹H NMR (DMSO-d₆, δ ppm)**: 1.21 (t, 3H, J= 7.2Hz, CH₂CH₃); 3.08 (s, 3H, C₄-CH₃); 3.68 (q, 2H, J= 7.2Hz, CH₂CH₃); 7.51-7.59 (m, 3H, C₆H₅-C_{3,4,5}-H); 8.00 (s, 1H, C₅-H); 8.20-8.27 (m, 2H, C₆H₅-C_{2,6}-H); 8.28 (s, 1H, NH, D₂O exchangeable). **MS, m/z (%)**: 390 (M⁺+1, 5.00), 60 (100.00).

Synthesis of 3-[(3,5-diamino-1H-pyrazol-4-yl)diazonyl]-4-methyl-6-phenylthieno[2,3-b]pyridine-2-carbonitrile; 23

A mixture of compound **21** (3.24 g, 10 mmol.) and excess hydrazine hydrate 99% (5 mL) in absolute ethanol (15 mL) was heated under reflux for 5 h. The reaction mixture was concentrated then allowed to cool. The obtained solid was filtered off, dried and recrystallized from ethanol.

Light brown powder; yield 2.13 g (57 %); m.p.: 195-197°C. **Anal. Calcd.** (%) for C₁₈H₁₄N₈S (374.42): C, 57.74; H, 3.77. **Found** (%): C, 57.91; H, 3.72. **IR (KBr, cm⁻¹)**: 3408, 3334, 3236, 3172 (NH, NH₂); 2924 (CH-aliph.); 2214 (C≡N); 1651 (C=N); 1565 (C=C); 1408 (N=N). **¹H NMR (DMSO-d₆, δ ppm)**: 2.90 (s, 3H, CH₃); 6.90 (s, 1H, NH, pyrazole-N₁-H, D₂O exchangeable); 7.30-7.40 (m, 1H, C₆H₅-C₄-H); 7.41-7.58 (m, 2H, C₆H₅-C_{3,5}-H); 7.95 (s, 1H, C₅-H); 8.10-8.30 (m, 2H, C₆H₅-C_{2,6}-H); 9.85 (s, 4H, two NH₂, pyrazole-C_{3,5}-NH₂, D₂O exchangeable).

Synthesis of 3-[2-(3-amino-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl]-4-methyl-6-phenylthieno[2,3-b]pyridine-2-carbonitrile; 24

Compound **22** (3.89 g, 10 mmol.) and excess hydrazine hydrate 99% (5 mL) in absolute ethanol (15 mL) was heated under reflux for 5 h. The reaction mixture was concentrated then allowed to cool. The obtained solid was filtered off, dried and recrystallized from ethanol.

Brown crystals; yield 2.68 g (69%); m.p.: 120-122°C. **Anal. Calcd.** (%) for C₁₈H₁₃N₇OS (375.41): C, 57.59; H, 3.49; N, 26.12. **Found** (%): C, 57.64; H, 3.53; N, 26.29. **IR (KBr, cm⁻¹)**: 3377, 3197 (NH, NH₂); 2928 (CH-aliph.); 2209 (C≡N); 1680 (C=O); 1646 (C=N); 1533 (C=C). **¹H NMR (DMSO-d₆, δ ppm)**: 2.79 (s, 3H, CH₃); 7.00 (s, 1H, pyrazole-NH, D₂O exchangeable); 7.22 (s, 2H, pyrazole-C₃-NH₂, D₂O exchangeable); 7.51-7.59 (m, 3H, C₆H₅-C_{3,4,5}-H); 7.82 (s, 1H, C₅-H); 8.10-8.28 (m, 2H, C₆H₅-C_{2,6}-H); 8.60 (s, 1H, C₃-NH, D₂O exchangeable).

Synthesis of 3-amino-2-(4,5-dihydro-1H-imidazol-2-yl)-4-methyl-6-phenyl-thieno[2,3-b]pyridine; 25

To a suspension of compound **2** (2.65 g, 10 mmol) in ethylene diamine (2.7 g, 3 mL, 40 mmol), carbon disulphide (1 mL) was added dropwise and the reaction mixture was heated on a water bath for 8 h. The reaction mixture was allowed to cool, and then triturated by ethanol. The obtained solid was filtered off, left to dry and recrystallized from ethanol.

Golden yellow crystals; yield 2.86g (94%); m.p.: 169-171°C. **Anal. Calcd.** (%) for C₁₇H₁₆N₄S (308.40): C, 66.21; H, 5.23; N,

18.17. **Found** (%): C, 66.28; H, 5.28; N, 18.34. **IR (KBr, cm⁻¹):** 3320, 3248 (NH, NH₂); 3050 (CH-aromatic); 2954, 2882 (CH-aliph.); 1665 (C=N); 1509 (C=C). **¹H NMR (DMSO-d₆, δ ppm):** 2.84 (s, 3H, CH₃); 3.43-3.45 (m, 2H, imidazolidine-C₄-H); 3.64-3.73 (m, 2H, imidazolidine-C₅-H); 6.90 (s, 1H, NH, D₂O exchangeable); 7.20 (s, 1H, NH₂, D₂O exchangeable); 7.60-8.15 (m, 6H, C₆H₅ & C₅-H). **MS, m/z (%)**: 308 (M⁺, 0.23), 60 (100.00).

Synthesis of 7-methyl-9-phenyl-2,3-dihydroimidazo[1,2-c]pyrido[3',2':4,5]-thieno[2,3-e]pyrimidine; 26

A mixture of compound **25** (0.34 g, 1.1 mmol), triethyl orthoformate (4.44 g, 5 mL, 30 mmol) and a catalytic amount of glacial acetic acid (0.2 mL) was heated under reflux for 8 h. The reaction mixture was allowed to cool and the precipitated solid was filtered off, left to dry and recrystallized from ethanol.

Buff crystals; yield 0.30 g (86%); m.p.: 165-167°C. **Anal. Calcd.** (%) for C₁₈H₁₄N₄S (318.40): C, 67.90; H, 4.43; N, 17.60. **Found** (%): C, 67.88; H, 4.48; N, 17.71. **IR (KBr, cm⁻¹):** 3000 (CH-aromatic); 2954, 2881 (CH-aliph.); 1508 (C=N); 1458 (C=C). **MS, m/z (%)**: 318 (M⁺, 19.36), 53 (100.00).

Synthesis of 7-methyl-5,9-diphenyl-2,3,5,6-tetrahydroimidazo[1,2-c]-pyrido[3',2':4,5]thieno[2,3-e]pyrimidine; 27

To a mixture of compound **25** (0.17 g, 0.6 mmol) and benzaldehyde (0.16 g, 0.15 mL, 1.5 mmol) in absolute ethanol (5 mL), 0.1 mL concentrated hydrochloric acid was added. The mixture was heated under reflux for 14 h. The reaction mixture was allowed to cool and the precipitated solid was filtered off, left to dry and recrystallized from ethanol.

Pale yellow powder; yield 0.21 g (72%); m.p.: > 360°C. **Anal. Calcd.** (%) for C₂₄H₂₀N₄S (396.51): C, 72.70; H, 5.08; N, 14.13. **Found** (%): C, 72.72; H, 5.08; N, 14.22. **IR (KBr, cm⁻¹):** 3427 (NH); 3052 (CH-aromatic); 2964, 2886 (CH-aliph.); 1596 (C=N); 1484 (C=C); 1327, 1086 (C-S-C). **¹H NMR (DMSO-d₆, δ ppm):** 3.09 (s, 3H, CH₃); 3.56-3.76 (m, 2H, imidazo-C₂-H); 4.10-4.20 (m, 2H, imidazo-C₃-H); 7.57-7.60 (m, 3H, C₅-C₆H₅-C_{3,4,5}-H); 7.69 (d, 2H, J = 8.4 Hz, C₅-C₆H₅-C_{2,6}-H); 7.89-7.95 (m, 4H, C₉-C₆H₅-C_{3,4,5}-H & C₈-H); 8.25-8.52 (m, 2H, C₅-C₆H₅-C_{2,6}-H); 8.71 (s, 1H, C₅-H); 9.65 (s, 1H, NH, D₂O exchangeable). **MS, m/z (%)**: 394 (M⁺ - 2, 0.18), 75 (100.00).

Synthesis of 7-methyl-9-phenyl-2,3,5,6-tetrahydroimidazo[1,2-c]pyrido-[3',2':4,5]thieno[2,3-e]pyrimidine-5-thione; 28

Compound **25** (2.28 g, 7.4 mmol) and excess carbon disulphide (10 mL) in anhydrous pyridine (20 mL) was heated under reflux for 20 h on a water bath. The reaction mixture was allowed to cool, and then poured onto crushed ice. The precipitated solid was filtered off, left to dry and recrystallized from ethanol.

Brown crystals; yield 1.9 g (73%); m.p.: 108-110°C. **Anal. Calcd.** (%) for C₁₈H₁₄N₄S₂ (350.46): C, 61.69; H, 4.03; N, 15.99. **Found** (%): C, 61.73; H, 4.02; N, 16.14. **IR (KBr, cm⁻¹):** 3246 (NH); 3000 (CH-aromatic); 2881 (CH-aliph.); 1650 (C=N); 1508 (C=C); 1457,

1273, 1200, 1051 (I, II, III, IV bands N-C=S); 1306, 1273 (C-S-C). **¹H NMR (DMSO-d₆, δ ppm):** 3.00 (s, 3H, CH₃); 3.81-3.83 (m, 2H, imidazo-C₂-H); 4.35-4.41 (m, 2H, imidazo-C₃-H); 7.50-7.70 (m, 3H, C₆H₅-C_{3,4,5}-H); 7.98 (s, 1H, C₈-H); 8.20-8.38 (m, 2H, C₆H₅-C_{2,6}-H); 9.85 (s, 1H, NH, D₂O exchangeable). **MS, m/z (%)**: 350 (M⁺, 0.02), 51 (100.00).

Synthesis of ethyl 3-azido-4-methyl-6-phenylthieno[2,3-b]pyridine carboxylate; 30

Compound **29** (3.12 g, 10 mmol) was dissolved in a mixture of concentrated sulphuric acid (2.5 mL) and water (7 mL) and cooled to 0-5°C in an ice bath. An aqueous solution of sodium nitrite (0.83 g, 120 mmol in 1 mL water) was added dropwise while stirring and maintaining the temperature below 5°C. Then, a solution of sodium azide (0.65 g, 10 mmol) in water (5 mL) was added dropwise to the reaction mixture while cooling. The reaction was stirred for 24 h at room temperature and the precipitated solid was filtered off, washed with water, left to dry and recrystallized from ethanol.

Light brown crystals; yield 2.56 g (76%); m.p.: > 360°C. **Anal. Calcd.** (%) for C₁₇H₁₄N₄O₂S (338.38): C, 60.34; H, 4.17; N, 16.56. **Found** (%): C, 60.37; H, 4.19; N, 16.69. **IR (KBr, cm⁻¹):** 3000 (CH-aromatic); 2923, 2856 (CH-aliph.); 2128 (N₃); 1680 (C=O); 1624 (C=N); 1233, 1010 (C-O-C). **MS, m/z (%)**: 339 (M⁺ + 1, 0.26), 338 (M⁺, 0.26), 80 (100.00).

General procedure for the synthesis of compounds 31a&b

Equimolar amounts of compound **30** (3.38 g, 10 mmol) and appropriate nitrile (10 mmol) namely; malononitrile and 2-(benzo[d]thiazol-2-yl)acetonitrile were added with vigorous stirring to a solution of sodium methoxide [prepared from 0.3 g sodium and 20 mL methanol]. The reaction mixture was stirred at room temperature for 24 h. Then, poured onto crushed ice. The obtained precipitate was filtered off, washed with water, left to dry and recrystallized from ethanol.

3-Cyano-10-methyl-8-phenylpyrido[3',2':4,5]thieno[2,3-e][1,2,3]triazolo-[1,5-a]pyrimidin-5(4H)-one; 31a

Dark red crystals; yield 3.21 g (90%); m.p.: > 360°C. **Anal. Calcd.** (%) for C₁₈H₁₀N₆OS (358.38): C, 60.33; H, 2.81; N, 23.45. **Found** (%): C, 60.34; H, 2.83; N, 23.52. **IR (KBr, cm⁻¹):** 3450 (OH broad); 3350, 3200 (NH); 2975 (CH-aliph.); 2202 (C≡N); 1710 (C=O); 1621 (C=N); 1590 (C=C); 1458 (N=N). **¹H NMR (DMSO-d₆, δ ppm):** 2.73 (s, 3H, CH₃); 6.94-7.20 (m, 3H, C₆H₅-C_{3,4,5}-H); 7.90 (s, 1H, C₉-H); 8.00-8.22 (m, 2H, C₆H₅-C_{2,6}-H); 8.52 (s, 1H, NH, D₂O exchangeable). **MS, m/z (%)**: 358 (M⁺, 15.11), 80 (100.00).

3-(1,3-Benzo[d]thiazol-2-yl)-10-methyl-8-phenyl pyrido[3',2':4,5]thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5(4H)-one; 31b

Buff crystals; yield 3.89 g (84%); m.p.: > 360°C. **Anal. Calcd.** (%) for C₂₄H₁₄N₆OS₂ (466.54): C, 61.79; H, 3.02; N, 18.01. **Found** (%): C, 61.85; H, 3.05; N, 18.12. **IR (KBr, cm⁻¹):** 3442 (OH tautomer); 3290, 3230 (NH); 3075 (CH-aromatic); 2890 (CH-aliph.); 1706

(C=O); 1641 (C=N); 1562 (C=C); 1414 (N=N). **MS, m/z (%)**: 467 ($M^+ + 1$, 1.67), 466 (M^+ , 13.75), 80 (100.00).

Synthesis of ethyl 4-methyl-3-(methylthiocarbonothioylamino)-6-phenylthieno-[2,3-b]pyridine-2-carboxylate; 32

To a vigorously stirred solution of compound **29** (3.12 g, 10 mmol) in dimethyl sulphoxide (5 mL) at room temperature, carbon disulphide (1.98 g, 1.6 mL, 26 mmol) and aqueous sodium hydroxide (0.8 g, 20 mmol in 2 mL water) were added simultaneously over a period of 30 min and the reaction was stirred for another 30 min. Dimethyl sulphate (2.5 g, 1.9 mL, 20 mmol) was then added dropwise to the reaction mixture while stirring which was continued for 24 h. The reaction mixture was poured onto crushed ice and the solid obtained was filtered, washed with water, dried and recrystallized from ethanol.

Orange powder; yield 3.52 g (81%); m.p.: > 360°C. **Anal. Calcd.** (%) for $C_{19}H_{18}N_2O_2S_3$ (402.55): C, 56.69; H, 4.51; N, 6.96. **Found** (%) : C, 56.72; H, 4.55; N, 7.08. **IR (KBr, cm^{-1})**: 3450 (NH); 3073 (CH-aromatic); 2920 (CH-aliph.); 1700 (C=O); 1470 (C=C); 1544, 1278, 1146, 1092 (N-C=S); 1278, 1092 (C-S-C); 1242, 1059 (C-O-C). **1H NMR (DMSO- d_6 , δ ppm)**: 1.0-1.15 (m, 3H, CH_2-CH_3); 2.71 (s, 3H, S- CH_3); 2.85 (s, 3H, C_4-CH_3); 4.26-4.43 (m, 2H, CH_2-CH_3); 7.32 (s, 1H, NH, D_2O exchangeable); 7.52-7.54 (m, 3H, $C_6H_5-C_{3,4,5}-H$); 7.85 (s, 1H, C_5-H); 8.17 (d, 2H, $J=8.1$ Hz, $C_6H_5-C_{2,6}-H$). **MS, m/z (%)**: 403 ($M^+ + 1$, 1.66), 401 ($M^+ - 1$, 0.38), 76 (100.00).

Synthesis of 3-amino-9-methyl-7-phenyl-2-thioxo-2,3-dihydropyrido [3',2':4,5]thieno[3,2-d]pyrimidin-4(1H)-one; 33

A mixture of compound **32** (4.02 g, 10 mmol) and excess hydrazine hydrate 99% (5 mL) in absolute ethanol (15 mL) was refluxed for 12 h until the methyl mercaptan evolution ceased. The reaction mixture was allowed to cool and the obtained solid was filtered off, washed with ethanol, left to dry and recrystallized from ethanol.

Yellow powder; yield 1.47 g (43%); m.p.: >360°C. **Anal. Calcd.** (%) for $C_{16}H_{12}N_4O_2S$ (340.42): C, 56.45; H, 3.55. **Found** (%) : C, 56.53; H, 3.58. **IR (KBr, cm^{-1})**: 3209, 3192 (NH, NH_2); 3025 (CH-aromatic); 2923 (CH-aliph.); 1740 (C=O); 1541, 1243, 1147, 1014 (N-C=S I, II, III, IV bands); 1541 (C=C). **1H NMR (DMSO- d_6 , δ ppm)**: 2.87 (s, 3H, CH_3); 4.30 (s, 2H, NH_2 , D_2O exchangeable); 6.61 (s, 1H, NH, D_2O exchangeable); 7.48-7.54 (m, 3H, $C_6H_5-C_{3,4,5}-H$); 7.81 (s, 1H, C_5-H); 8.15 (d, 2H, $J=7.95$ Hz, $C_6H_5-C_{2,6}-H$). **MS, m/z (%)**: 340 (M^+ , 0.07), 71 (100.00).

Synthesis of ethyl 4-methyl-6-phenyl-3-(1H-tetrazol-1-yl)thieno[2,3-b]-pyridine-2-carboxylate; 34

Equimolar amounts of compound **29** (3.12 g, 10 mmol), triethyl orthoformate (1.48 g, 1.64 mL, 10 mmol) and sodium azide (0.65 g, 10 mmol) were heated under reflux in glacial acetic acid (40 mL) for 8 h. The reaction mixture was allowed to cool then triturated with concentrated hydrochloric acid (7 mL).

The solid obtained was filtered, washed with water, dried and recrystallized from ethanol.

Buff crystals; yield 2.56 g (70%); m.p.: > 360°C. **Anal. Calcd.** (%) for $C_{18}H_{15}N_5O_2S$ (365.41): C, 59.16; H, 4.14; N, 19.17. **Found** (%) : C, 59.18; H, 4.21; N, 19.25. **IR (KBr, cm^{-1})**: 3025 (CH-aromatic); 2857 (CH-aliph.); 1701 (C=O); 1641 (C=N); 1561 (C=C); 1414 (N=N); 1200, 1021 (C-O-C). **MS, m/z (%)**: 368 ($M^+ + 3$, 4.55), 51 (100.00).

Synthesis of 2,3-diamino-9-methyl-7-phenyl-3,4-dihydropyrido[3',2':4,5]-thieno[3,2-d]pyrimidin-4-one; 35

Compound **34** (3.65 g, 10 mmol.) was refluxed in excess hydrazine hydrate 99% (5 mL) for 10 h. The reaction mixture was allowed to cool, poured onto crushed ice and the solid obtained was filtered, washed with ethanol, dried and recrystallized from ethanol.

White crystals; yield 2.81 g (77%); m.p.: 280-282°C. **Anal. Calcd.** (%) for $C_{16}H_{13}N_5OS$ (323.37): C, 59.43; H, 4.05; N, 21.66. **Found** (%) : C, 59.55; H, 4.04; N, 21.69. **IR (KBr, cm^{-1})**: 3431, 3352, 3212 (NH_2); 3054 (CH-aromatic); 2918 (CH-aliph.); 1700 (C=O); 1673 (C=N); 1580 (C=C). **1H NMR (DMSO- d_6 , δ ppm)**: 2.71 (s, 3H, CH_3); 4.10 (s, 2H, C_2-NH_2 , D_2O exchangeable); 6.80 (s, 2H, N_3-NH_2 , D_2O exchangeable); 7.41-7.47 (m, 3H, $C_6H_5-C_{3,4,5}-H$); 7.52 (s, 1H, C_5-H); 8.05 (d, 2H, $J=7.2$ Hz, $C_6H_5-C_{2,6}-H$). **MS, m/z (%)**: 323 (M^+ , 1.31), 57 (100.00).

Synthesis of ethyl N-(9-methyl-4-oxo-7-phenyl-pyrido [3',2':4,5]thieno[3,2-d]-pyrimidin-3(4H)-yl)formimidate; 37

The carbohydrazide derivative **36** (2.98 g, 10 mmol) was refluxed with double the amounts of triethyl orthoformate (2.9 g, 3 mL, 20 mmol.) in acetic anhydride (10 mL) for 10 h. The reaction mixture was allowed to cool and the solid product was filtered, washed with ethanol, left to dry and recrystallized from ethanol.

Brown crystals; yield 2.62 g (72%); m.p.: 108-110°C. **Anal. Calcd.** (%) for $C_{19}H_{16}N_4O_2S$ (364.42): C, 62.62; H, 4.43; N, 15.37. **Found** (%) : C, 62.69; H, 4.47; N, 15.43. **IR (KBr, cm^{-1})**: 3090 (CH-aromatic); 2919, 2852 (CH-aliph.); 1736 (C=O); 1660 (C=N); 1546 (C=C); 1213, 1023 (C-O-C). **1H NMR (DMSO- d_6 , δ ppm)**: 1.16-1.23 (m, 3H, CH_2CH_3); 2.71 (s, 3H, C_9-CH_3); 4.10-4.20 (m, 2H, CH_2-CH_3); 7.40-7.60 (m, 3H, $C_6H_5-C_{3,4,5}-H$); 7.87 (s, 1H, $N_3-N=CH$); 7.92 (s, 1H, C_5-H); 8.10-8.30 (m, 2H, $C_6H_5-C_{2,6}-H$); 8.36 (s, 1H, C_2-H). **MS, m/z (%)**: 363 ($M^+ - 1$, 0.24), 53 (100.00).

Synthesis of N-(9-methyl-4-oxo-7-phenylpyrido[3',2':4,5]thieno[3,2-d]pyrimidin-3(4H)-yl)acetamide; 38

The carbohydrazide derivative **36** (2.98 g, 10 mmol) was heated under reflux in acetic anhydride (10 mL) for 10 h. The reaction mixture was allowed to cool, poured onto crushed ice and the separated solid was filtered, washed with water, dried and recrystallized from ethanol.

Yellow crystals; yield 2.50 g (69%); m.p.: >360°C. **Anal. Calcd.** (%) for $C_{19}H_{16}N_4O_2S$ (364.42): C, 62.62; H, 4.43; N, 15.37.

Found (%): C, 62.61; H, 4.48; N, 15.46. **IR (KBr, cm⁻¹)**: 3259 (NH); 3058 (CH-aromatic); 2919, 2852 (CH-aliph.); 1695 (C=O pyrimidinone); 1673 (C=O acetyl); 1579 (C=N); 1544 (C=C). **MS, m/z (%)**: 364 (M⁺, 2.43), 53 (100.00).

Synthesis of 1-(3-amino-4-methyl-6-phenylthieno[2,3-b]pyridine-2-carbonyl)-3-methyl-1H-pyrazol-5(4H)-one; 39
An equimolar mixture of the carbohydrazide derivative **36** (2.98 g, 10 mmol) and ethyl acetoacetate (1.30 g, 1.3 mL, 10 mmol) in ethanolic sodium ethoxide solution [prepared by dissolving sodium metal (0.12 g, 5 mmol) in absolute ethanol 30 mL], was heated under reflux for 10 h. The reaction mixture was allowed to cool and the obtained product was filtered, washed with ethanol, left to dry and recrystallized from ethanol. Brown needle crystals; yield 2.74 g (75%); m.p.: 85-87°C. **Anal. Calcd. (%) for C₁₉H₁₆N₄O₂S (364.42)**: C, 62.62; H, 4.43; N, 15.37. **Found (%)**: C, 62.67; H, 4.45; N, 15.48. **IR (KBr, cm⁻¹)**: 3430, 3350 (NH₂); 3085 (CH-aromatic); 2927 (CH-aliph.); 1735, 1688 (two C=O); 1641 (C=N); 1553 (C=C). **¹H NMR (DMSO-d₆, δ ppm)**: 2.26 (s, 5H, pyrazole-C₃-CH₃ and pyrazole-C₄-H); 2.81 (s, 3H, C₄-CH₃); 7.46-7.60 (m, 3H, C₆H₅-C_{3,4,5}-H); 7.84 (s, 1H, C₅-H); 8.14 (d, 2H, J=7.5Hz, C₆H₅-C_{2,6}-H); 16.53 (s, 2H, H-bonded NH₂, D₂O exchangeable). **MS, m/z (%)**: 364 (M⁺, 1.30), 363 (M⁺-1, 1.30), 65 (100.00).

Biological evaluation

Mammalian cell lines

MCF-7 cells (human breast cancer cell line) were obtained from VACSERA Tissue culture unit. HepG2 cells (human cell line of a well differentiated hepatocellular carcinoma isolated from a liver biopsy of a male Caucasian aged 15 years) were obtained from the American type culture collection (ATCC).

Cell line Propagation

The cells were propagated in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum, 1% L-glutamine, HEPES buffer and 50 µg/mL gentamycin. All cells were maintained at 37°C in a humidified atmosphere with 5% CO₂ and were subcultured two times a week.

Cytotoxicity evaluation using viability assay

For cytotoxicity assay, the cells were seeded in 96-well plate at a cell concentration of 1x10⁴ cells per well in 100 µL of growth medium. Fresh medium containing different concentrations of the test sample was added after 24 h of seeding. Serial two-fold dilutions of the tested chemical compounds were added to confluent cell monolayers dispensed into 96-well, flat-bottomed microtiter plates (Falcon, NJ, USA) using a multichannel pipette. The microtiter plates were incubated at 37°C in a humidified incubator with 5% CO₂ for a period of 48 h. Three wells were used for each concentration of the test sample. Control cells were incubated without test sample and with or without DMSO. The little percentage of

DMSO present in the wells (maximal 0.1%) was found not to affect the experiment.

After incubation of the cells for 24 h at 37°C, various concentrations of sample (50, 25, 12.5, 6.25, 3.125 & 1.56 µg) were added, and the incubation was continued for 48 h and viable cells yield was determined by a colorimetric method. After the end of the incubation period, media were aspirated and the crystal violet solution (1%) was added to each well for at least 30 minutes. The stain was removed and the plates were rinsed using tap water until all excess stain is removed. Glacial acetic acid (30%) was then added to all wells and mixed thoroughly, and then the absorbance of the plates were measured after gentle shaking on Microplate reader (TECAN, Inc.), using a test wavelength of 490 nm. All results were corrected for background absorbance detected in wells without added stain. All experiments were carried out in triplicate. The cell cytotoxic effect of each tested compound was calculated [52,53]. The cytotoxicity of the tested compounds was estimated in terms of percent growth inhibition compared to untreated control cells and their IC₅₀ in µM/L which is the concentration of the compound that inhibits the tumor cell growth by 50%.

Conclusion

Most of the compounds showed better activity against liver cancer HepG2 cell line than breast cancer MCF-7 cell line. However, compounds **4, 5, 7, 11, 12, 23, 24, 28, 37, 38** and **39** showed moderate to strong activity against HepG2 with IC₅₀ values ranging from 10.33-43.90 µM/L. While compounds **3, 5, 7, 12, 16, 23, 24, 37** and **39** were the most potent against MCF-7 cell line exerting IC₅₀ values ranging from 9.70-48.80 µM/L. Which revealed that, compounds **5, 7, 12, 23, 24, 37** and **39** exerted potent anticancer activities against both cell lines from which the pyrido[3',2':4,5]thieno[3,2-b]pyridine derivative **5** was the most active compound exerting anticancer activity comparable to the reference drug doxorubicin against both HepG2 and MCF-7 cell lines showing IC₅₀ values 10.33 and 9.70 µM/L; respectively, while doxorubicin exerted its IC₅₀ values at 8.55 and 8.90 µM/L; respectively.

Competing interests

The authors declare that they have no competing interests.

Acknowledgement

To the Regional Center for Mycology and Biotechnology, Al-Azhar University for carrying out the biological anticancer screening.

Publication history

Senior Editor: Rafael Luque, University of Cordoba, Spain.

Editors: Elias A. Couladouros, Agricultural University of Athens, Greece. Branko Stanovnik, University of Ljubljana, Slovenia.

Received: 23-Nov-2013 Revised: 17-Dec-2013

Re-Revised: 21-Dec-2013 Accepted: 24-Dec-2013

Published: 31-Dec-2013

References

1. Wu JP, Fleck R, Brickwood J, Capolino A and Catron K. **The discovery of thienopyridine analogues as potent IkappaB kinase beta inhibitors. Part II.** *Bioorg Med Chem Lett.* 2009; **19**:5547-51. | [Article](#) | [PubMed](#)
2. Willemann C, Grunert R, Bednarski PJ and Troschütz R. **Synthesis and cytotoxic activity of 5,6-heteroaromatically annulated pyridine-2,4-diamines.** *Bioorg Med Chem.* 2009; **17**:4406-19. | [Article](#) | [PubMed](#)
3. Lockman JW, Reeder MD, Suzuki K, Ostanin K, Hoff R, Bhoite L, Austin H, Baichwal V and Adam Willardsen J. **Inhibition of eEF2-K by thieno[2,3-b]pyridine analogues.** *Bioorg Med Chem Lett.* 2010; **20**:2283-6. | [Article](#) | [PubMed](#)
4. Zeng XX, Zheng RL, Zhou T, He HY, Liu JY, Zheng Y, Tong AP, Xiang ML, Song XR, Yang SY, Yu LT, Wei YQ, Zhao YL and Yang L. **Novel thienopyridine derivatives as specific anti-hepatocellular carcinoma (HCC) agents: synthesis, preliminary structure-activity relationships, and in vitro biological evaluation.** *Bioorg Med Chem Lett.* 2010; **20**:6282-5. | [Article](#) | [PubMed](#)
5. Pevet I, Brule C, Tizot A, Gohier A, Cruzalegui F, Boutin JA and Goldstein S. **Synthesis and pharmacological evaluation of thieno[2,3-b]pyridine derivatives as novel c-Src inhibitors.** *Bioorg Med Chem.* 2011; **19**:2517-28. | [Article](#) | [PubMed](#)
6. Mohareb RM, Wardakhan WW, Elmegeed GA and Ashour RM. **Heterocyclizations of pregnenolone: novel synthesis of thiosemicarbazone, thiophene, thiazole, thieno[2,3-b]pyridine derivatives and their cytotoxicity evaluations.** *Steroids.* 2012; **77**:1560-9. | [Article](#) | [PubMed](#)
7. Feng L, Reynisdóttir I and Reynisson J. **The effect of PLC-g2 inhibitors on the growth of human tumour cells.** *Eur. J. Med.Chem.* 2012; **54**:463-469. | [Article](#)
8. Dai XY, Zeng XX, Peng F, Han YY, Lin HJ, Xu YZ, Zhou T, Xie G, Deng Y, Mao YQ, Yu LT, Yang L and Zhao YL. **A novel anticancer agent, SKLB70359, inhibits human hepatic carcinoma cells proliferation via G0/G1 cell cycle arrest and apoptosis induction.** *Cell Physiol Biochem.* 2012; **29**:281-90. | [Article](#) | [PubMed](#)
9. Mohareb R.M, Abdallah A.E and Abdelaziz M.A. **New approaches for the synthesis of pyrazole, thiophene, thieno[2,3-b]pyridine and thiazole derivatives together with their anti-tumor evaluations.** *Med. Chem. Res.* 2013. | [Article](#)
10. Schnute ME, Anderson DJ, Brideau RJ, Ciske FL and Collier SA. **2-Aryl-2-hydroxyethylamine substituted 4-oxo-4,7-dihydrothieno[2,3-b]pyridines as broad-spectrum inhibitors of human herpesvirus polymerases.** *Bioorg Med Chem Lett.* 2007; **17**:3349-53. | [Article](#) | [PubMed](#)
11. Pinheiro L.C.S, Borges J.C, Oliveira C.D, Ferreira V.F and Romeiro G.A. **Synthesis of new (phenylamino)thieno [2,3-b]pyridines and derivatives of the novel benzo[b]thieno[3,2-h]-1,6-naphthyridinetetracyclic system.** *Arkivoc.* 2008; **17**:77-87. | [Article](#)
12. Shuck-Lee D, Chen F.F, Willard R, Raman S and Ptak R. **Heterocyclic Compounds That Inhibit Rev-RRE Function and Human Immunodeficiency Virus Type 1 Replication.** *Antimicrob. Agents Chemother.* 2008; **52**:3169-3179. | [Article](#)
13. Chaubey A and Pandeya S.N. **Pyridine" a versatile nucleuse in pharmaceutical field.** *Asian J. Pharm. Clin. Res.* 2011; **4**:5-8. | [Pdf](#)
14. Boschelli DH, Wu B, Barrios Sosa AC, Chen J, Asselin M, Cole DC, Lee J, Yang X and Chaudhary D. **Synthesis and PKCtheta inhibitory activity of a series of 4-(indol-5-ylamino)thieno[2,3-b]pyridine-5-carbonitriles.** *Bioorg Med Chem Lett.* 2008; **18**:2850-3. | [Article](#) | [PubMed](#)
15. Nathan Tumey L, Boschelli DH, Lee J and Chaudhary D. **2-Alkenylthieno[2,3-b]pyridine-5-carbonitriles: Potent and selective inhibitors of PKCtheta.** *Bioorg Med Chem Lett.* 2008; **18**:4420-3. | [Article](#) | [PubMed](#)
16. Madhusudana K, Shireesha B, Naidu VG, Ramakrishna S, Narsaiah B, Rao AR and Diwan PV. **Anti-inflammatory potential of thienopyridines as possible alternative to NSAIDs.** *Eur J Pharmacol.* 2012; **678**:48-54. | [Article](#) | [PubMed](#)
17. Liu H, Li Y, Wang XY, Wang B, He HY, Liu JY, Xiang ML, He J, Wu XH and Yang L. **Synthesis, preliminary structure-activity relationships, and in vitro biological evaluation of 6-aryl-3-amino-thieno[2,3-b]pyridine derivatives as potential anti-inflammatory agents.** *Bioorg Med Chem Lett.* 2013; **23**:2349-52. | [Article](#) | [PubMed](#)
18. Bernardino AM, da Silva Pinheiro LC, Rodrigues CR, Loureiro NI, Castro HC, Lanfredi-Rangel A, Sabatini-Lopes J, Borges JC, Carvalho JM, Romeiro GA, Ferreira VF, Frugulhetti IC and Vannier-Santos MA. **Design, synthesis, SAR, and biological evaluation of new 4-(phenylamino)thieno[2,3-b]pyridine derivatives.** *Bioorg Med Chem.* 2006; **14**:5765-70. | [Article](#) | [PubMed](#)
19. Al-Trawneh SA, El-Abdelah MM, Zahra JA, Al-Taweel SA, Zani F, Incerti M, Cavazzoni A and Vicini P. **Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.** *Bioorg Med Chem.* 2011; **19**:2541-8. | [Article](#) | [PubMed](#)
20. Moretto AF, Kirincich SJ, Xu WX, Smith MJ, Wan ZK, Wilson DP, Follows BC, Binnun E, Joseph-McCarthy D, Foreman K, Erbe DV, Zhang YL, Tam SK, Tam SY and Lee J. **Bicyclic and tricyclic thiophenes as protein tyrosine phosphatase 1B inhibitors.** *Bioorg Med Chem.* 2006; **14**:2162-77. | [Article](#) | [PubMed](#)
21. Bahekar RH, Jain MR, Goel A, Patel DN, Prajapati VM, Gupta AA, Jadav PA and Patel PR. **Design, synthesis, and biological evaluation of substituted-N-(thieno[2,3-b]pyridin-3-yl)-guanidines, N-(1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidines, and N-(1H-indol-3-yl)-guanidines.** *Bioorg Med Chem.* 2007; **15**:3248-65. | [Article](#) | [PubMed](#)
22. Bahekar RH, Jain MR, Jadav PA, Prajapati VM, Patel DN, Gupta AA, Sharma A, Tom R, Bandyopadhyaya D, Modi H and Patel PR. **Synthesis and antidiabetic activity of 2,5-disubstituted-3-imidazol-2-yl-pyrrolo[2,3-b]pyridines and thieno[2,3-b]pyridines.** *Bioorg Med Chem.* 2007; **15**:6782-95. | [Article](#) | [PubMed](#)
23. Kamata M, Yamashita T, Kina A, Funata M, Mizukami A, Sasaki M, Tani A, Funami M, Amano N and Fukatsu K. **Design, synthesis, and structure-activity relationships of novel spiro-piperidines as acetyl-CoA carboxylase inhibitors.** *Bioorg Med Chem Lett.* 2012; **22**:3643-7. | [Article](#) | [PubMed](#)
24. Adachi I, Hiramatsu Y, Ueda M and Kawakami M. **4,7-dihydrothieno[2,3-b] pyridine derivatives useful in the treatment of cardiovascular diseases.** *US Patent.* 1987; **4**:703-051.
25. Adachi I, Yamamori T, Hiramatsu Y, Sakai K, Mihara S, Kawakami M, Masui M, Uno O and Ueda M. **Studies on dihydropyridines. III. Synthesis of 4,7-dihydrothieno [2,3-b]-pyridines with vasodilator and antihypertensive activities.** *Chem Pharm Bull (Tokyo).* 1988; **36**:4389-402. | [Article](#) | [PubMed](#)
26. Ueda M, Matsumura S, Masui M, Matsuura E, Kawakami M, Fujitomo H, Umeda T, Kagawa H, Hirohata S, Shima K and et al. **Pharmacological studies on a new dihydrothienopyridine calcium antagonist. 3rd communication: antihypertensive effects of S-(+)-methyl-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)thieno[2, 3-b] pyridine-5-carboxylate in hypertensive rats and dogs.** *Arzneimittelforschung.* 1993; **43**:1282-90. | [PubMed](#)
27. Ohba S, Nakajima K, Komiyama Y, Kugimiya F, Igawa K, Itaka K, Moro T, Nakamura K, Kawaguchi H, Takato T and Chung UI. **A novel osteogenic helioxanthin-derivative acts in a BMP-dependent manner.** *Biochem Biophys Res Commun.* 2007; **357**:854-60. | [Article](#) | [PubMed](#)
28. Saito K, Nakao A, Shinozuka T, Shimada K, Matsui S, Oizumi K, Yano K, Ohata K, Nakai D, Nagai Y and Naito S. **Discovery and structure-activity relationship of thienopyridine derivatives as bone anabolic agents.** *Bioorg Med Chem.* 2013; **21**:1628-42. | [Article](#) | [PubMed](#)
29. Buchstaller HP, Siebert CD, Steinmetz R, Frank I, Berger ML, Gottschlich R, Leibrock J, Krug M, Steinhilber D and Noe CR. **Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor.** *J Med Chem.* 2006; **49**:864-71. | [Article](#) | [PubMed](#)
30. Mohler EG, Shacham S, Noiman S, Lezoualc'h F, Robert S, Gastineau M, Rutkowski J, Marantz Y, Dumuis A, Bockaert J, Gold PE and Ragozzino ME. **VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux.** *Neuropharmacology.* 2007; **53**:563-73. | [Article](#) | [PubMed](#)
31. Le U, Melancon BJ, Bridges TM, Vinson PN, Utley TJ, Lamsal A, Rodriguez

- AL, Venable D, Sheffler DJ, Jones CK, Blobaum AL, Wood MR, Daniels JS, Conn PJ, Niswender CM, Lindsley CW and Hopkins CR. **Discovery of a selective M(4) positive allosteric modulator based on the 3-amino-thieno[2,3-b]pyridine-2-carboxamide scaffold: development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophrenia.** *Bioorg Med Chem Lett.* 2013; **23**:346-50. | [Article](#) | [PubMed](#)
32. Hassan A.Y and Fayz F.M. **Synthesis and Reactions of some pyridine and thieno[2,3-b]pyridine derivatives with expected biological activity.** *Al-Azhar Bull. Sci.* 2008; **19**:67-90.
33. Patil S. P, Kazi M.A, Kanawade S.B, Nikam P.S, Jachak M.N and Toche R.B. **Expedient approach for the synthesis of novel indenothiophene derivatives.** *Monatsh Chem.* 2012; **143**:317–323. | [Article](#)
34. Hu H, Zhang A and Ding L. **Facile synthesis of novel tacrine analogues.** *J. Chem. Res.* 2009; **25**: 562-564. | [Article](#)
35. Shireesha B, Raghuram Rao A, Narsaiah B, Ramakrishna S, Madhusudhana and Yakaiah T. *US patent , PCT/IN2010/000005*, (2010).
36. Ghorab M.M and Hassan A.Y. **Synthesis and antibacterial properties of new dithienyl containing pyran, pyrano[2,3-b] pyridine, pyrano[2,3-d] pyrimidine and pyridine derivatives.** *Phosphorus,Sulfur, Silicon.* 1998; **141**:251-261. | [Article](#)
37. Gaber, H.M.; Sherif, S.M.; Abu-Shanab, F.A.; “**Studies on heterocyclic β -enaminonitriles: Synthesis of new condensed thieno[2,3-b]pyridines containing N- heterocyclic moieties.** *J. Sulfur Chem.* 2005; **26**: 393– 403. | [Article](#)
38. Hossain M.I and Bhuiyan M.M.H. **Synthesis and Antimicrobial Activities of Some New Thieno and Europyrimidine Derivatives.** *J. Sci. Res.* 2009; **2**:317-325. | [Article](#)
39. El-Sayed Ali T. **Synthesis of some novel pyrazolo[3,4-b]pyridine and pyrazolo[3,4-d]pyrimidine derivatives bearing 5,6-diphenyl-1,2,4-triazine moiety as potential antimicrobial agents.** *Eur J Med Chem.* 2009; **44**:4385-92. | [Article](#) | [PubMed](#)
40. Al-Omran F.A and El-Khair A.A. **Novel synthesis of thieno[2,3-b]pyridine and substituted 2-thienylthiourea derivatives as antibiotic agents.** *J. Heterocycl. Chem.* 2004; **41**:909-914. | [Article](#)
41. Ahmed E.M, Marzouk N.A, Hessien S.A and Ali A.M. “**Synthesis, Reactions and Antimicrobial Activity of Some New Thienopyridine and Thienopyrimidine Derivatives.** *World J. Chem.* 2011; **6**:25-31. | [Pdf](#)
42. Dave C.G and Shah R.D. “**Synthesis of isomeric triazolopyrrolopyrimidines.** *J. Heterocycl. Chem.* 2000; **37**:757-761. | [Article](#)
43. Ibrahim L.I, Tammam G.H and Abdin T.M.S. **Synthesis of New Thieno[2,3-d]pyrimidine Derivatives.** *J. Chem. Soc. Pak.* 1989; **11**:227-231. | [Pdf](#)
44. El-Louh A.K.K. “**o-Aminonitrile in Heterocyclic chemistry: Synthesis of Thienopyridine, Pyridothienopyrimidine, Pyridothieno[1,2,4] triazolopyrimidine, Pyridothienopyridine Derivatives.** *J. Al-Azhar University-Gaza (natural Sciences).* 2008; **10**:1-20.
45. El-Essawy F.A, Hawatta M.A, Abdel-Megied A.E.-S and El-Sherbeny D.A. **Synthesis of Some Fused Heterocycles Based on Thieno[2,3-b]pyridine and Their Antimicrobial Activity.** *Chem. Heterocycl.Compds.* 2010; **46**:325-333. | [Article](#)
46. Ghorab M.M, Hassan A.Y and Nassar O.M. **Synthesis of Novel Heterocyclic Compounds for Antitumor and Radioprotective Activities.** *Phosphorus Sulfur Silicon.* 1998; **134**:447-462. | [Article](#)
47. Pokhodylo N.T, Matychuk V.S and Obushak N.D. **Synthesis of A New Heterocyclic System – Pyrido[3',2':4,5]thieno[2,3-e][1,2,3]triazolo[1,5-a] pyrimidine.** *Chem. Heterocycl.Compds.* 2009; **45**:881-883. | [Article](#)
48. Alagarsamy, V.; Shankar, D.; Solomon,V. R.; “**Synthesis of some novel 2-mercapto-3-(substitutedamino)-5,6,7,8-tetrahydro-3H-benzo[4,5] thieno[2,3-d]pyrimidin-4-ones as analgesic and anti-inflammatory agents.** *Arkivoc.* 2006; **16**:149-159. | [Article](#)
49. Abu-Hashem A.A, Abu-Zied K.M and El-Shehry M.F. **Synthetic utility of bifunctional thiophene derivatives and antimicrobial evaluation of the newly synthesized agents.** *Monatsh. Chem.* 2011; **142**:539–545. | [Article](#)
50. Al-Kamali A.S.N, Al-Hazmi A.A, Alhousami M.H.M and Al-Masany M.A. **Synthesis and antibacterial activity of some novel thieno[2,3-c] pyridazines using 3-amino-5-phenyl-2-ethoxycarbonylthieno[2,3-c] pyridazine as a starting material.** *Arab. J. Chem.* 2011. | [Article](#)
51. Samshuddin S, Narayana B, Sarojini B.K, Shetty D, and Kumari N.S. **Synthesis, characterization and biological evaluation of some new functionalized terphenyl derivatives.** *International Journal of Medicinal Chemistry .* 2012. | [Article](#)
52. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods.* 1983; **65**:55-63. | [Article](#) | [PubMed](#)
53. Vijayan P, Raghu C, Ashok G, Dhanaraj SA and Suresh B. **Antiviral activity of medicinal plants of Nilgiris.** *Indian J Med Res.* 2004; **120**:24-9. | [PubMed](#)

Citation:

Hassan AY, Sarg MT, Said MM and El-Sebaey SA. **Utility of thieno[2,3-b] pyridine derivatives in the synthesis of some condensed heterocyclic compounds with expected biological activity.** *Univers Org Chem.* 2013; **1**:2.
<http://dx.doi.org/10.7243/2053-7670-1-2>